Replimune Group Inc REPL

Healthcare Biotechnology

Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.

NDAQ:REPL - Post by User

Replimune Group Inc

<< Previous

Bullboard Posts

Post by StockHorizon Nov 25, 2024 10:09am

16 Views

Post# 36328910

Bullish Signals for $MYNZ and $REPL

$MYNZ maintains solid support at 0.20, showing resilience with a bullish MACD crossover—watch for momentum above 0.23. $REPL has broken out of its two-year downtrend, signaling a potential move higher as volume flows in. Both are setting up for strong upside.

<< Previous

Bullboard Posts

Sirios Resource discovers visible gold in Quebec